Twitter Beğeni Hilesi

New research into the link between APOE4 and the risk of developing Alzheimer’s has hit the headlines today. Our Chief Medical Officer Jonathan Schott helps us break down what these findings mean. alzheimersresearchuk.org/news/inheritin…

Wonderful to meet brilliant colleagues and celebrate the many succeses of UCL staff at a special reception at UCL East - a first visit for many of us! Jonathan Schott Rimona Weil Steve Fleming

Next week is Dementia Action Week, an annual campaign uniting people to act on dementia. We’re excited to hear from our past grantee Jonathan Schott who’s speaking at the Alzheimer's Society Alzheimer’s Annual Conference about the future of diagnosis. alzheimers.org.uk/dementia-profe…

The final session at the Alzheimer's Society conference and we are hearing from Jonathan Schott about the blood based biomarker challenge he is leading.

Thanks for the interview; privileged to lead the ADAPT study with Jonathan Schott UCL - buzzing from our first in person steering group meeting with protocol drafting, patient/public engagement, staff recruitment and collaboration with Imperial College London LSE University of Kent all underway!

📣 🩸 Jonathan Schott from UCL Queen Square Institute of Neurology discusses the increased accuracy of blood tests in relation to dementia.🩸 📣 More on this here - bit.ly/3V2MoH7

Best collaboration ever? Alzheimer's Research UK Cadbury UK #DementiaResearch #memories #200years #chocolate

Whoever comes to power on July 4th needs to double down on dementia prevention, diagnosis, treatment, research and care. This manifesto clearly lays out the challenges and what is needed 👏

🚨 Donanemab - a new Alzheimer’s drug - has just been approved for use in the US. Donanemab remains under consideration by GB’s regulator - MHRAgovuk - with a decision expected in the coming months. We've answered your key questions about the drug here... 👇

Calling non-professionals interested in dementia — register *for free* for this new online and in person event this Thursday — and hear the latest updates from Alzheimer's Association #AAIC24 — >2000 have signed up so far… alz.org/aaicforall

The collection of #blood #biomarkers studies using NULISA as presented at day two of #AAIC2024 is now available as a pre-print 🩸🧪🧠 medrxiv.org/content/10.110… Andrea L. Benedet Marc Suárez-Calvet 🧠🧪 🩺🌈 @Alamarbio Jonathan Schott Barbara Alessandro Padovani Göteborgs universitet / University of Gothenburg Barcelonaβeta Brain Research Center

Great talk by Will Coath using the MRC LHA @ UCL 1946 cohort to explore the timing pf and relationship between amyloid and tau positivity with age #AAIC24

Estarellas et al. report that an adapted Subtype and Stage Inference algorithm accommodates missing data in multimodal #Alzheimersdisease studies. Mar Estarellas MIG POND UCL Neil Oxtoby (Toybox Science) Jonathan Schott Daniel Alexander Alex Young edin.ac/3SjesUI

Fantastic talk by @joshkingrobson exploring the effects of midlife shift work on brain pathology 40 years later in the MRC LHA @ UCL 1946 birth cohort. Spoiler alert — shift workers have more vascular risk factors, smaller brains but *less* amyloid. More to follow! #AAIC24

Still not too late to sign up! alz.org/aaic-for-all/o…

Pleased to contribute to this great overview of the fast moving field of blood based biomarkers for Alzheimer’s disease — great to see our ADAPT study getting a mention Alzheimer's Research UK Alzheimer's Society UCL Brain Sciences

Blood tests could soon predict your risk of Alzheimer’s, potentially revolutionising early detection and treatment. “The pace of development of these tests is extraordinary” says Professor Jonathan Schott, UCL Queen Square Institute of Neurology Read more in nature: go.nature.com/3WHL7Vx

Bittersweet news as Alzheimer's drug #lecanemab has been licensed for use in Britain but won't be available on the #NHS. It's a remarkable achievement that we now have a drug that can slow Alzheimer's, but it's clear the NHS is not ready to deliver it.

New paper just out — combining the MRC LHA @ UCL Insight 46 and Lothian cohorts to examine cardiometabolic and ApoE4 effects on brain age. TLDR — key findings summarised below Research at ARUK UCL Brain Sciences Alzheimer's Association

Great to see this out! A great multi-centre academic and industry collaboration UCL Queen Square Institute of Neurology UCL Brain Sciences UK Dementia Research Institute Göteborgs universitet / University of Gothenburg Fujirebio Europe Eli Lilly and Company AlamarBio Quanterix … and many more